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SUMMARY Introduction: Mediastinal paragangliomas are low incidence tumors that arise from neural crest. 
Its diferential diagnosis include several malignant diseases, so its correct characterization is 
mandatory for an adecuate therapeutic management. 111In-Pentetreotide scintigraphy/SPECT-
CT can detect paraganglioma, mainly in those cases of atypical or unsuspected location, and 
may have a significant role in follow-up of those patients diagnosed with multifocal and familiar 
paraganglioma. Case: Here we report a case of an extremely rare middle mediastinal paragan-
glioma, detected by scintigraphy and SPECT-CT with 111In-Pentetreotide in a patient diagnosed 
of multifocal and family history of paraganglioma. Surgery was carried out by median ster-
notomy and extracorporeal circulation. The pathological examination of the surgical specimen 
showed a para-aortic low-grade tumor, positive for chromogranin and synaptophysin, cy-
tokeratin AE1-AE3 negative and Ki67 lower than 5%, compatible with paraganglioma. Cur-
rently, the patient is tumor free, under clinical monitoring. Conclusions: 111In- Pentetreotide 
scan proved to be a helpful diagnostic method because of its potential to explore full body, so 
It allows us to locate unsuspected and atypical location paragangliomas. This finding suggests 
that patients diagnosed with multifocal head and neck paraganglioma should undergo periodi-
cal follow-up with 111In-Pentetreotide scan to detect unsuspected paraganglioma. 
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RESUMEN Introducción: Los paragangliomas mediastínicos son tumores de baja incidencia que surgen 
de la cresta neural. Su diagnóstico diferencial incluye varias enfermedades malignas, por lo 
que su correcta caracterización es obligatoria para un adecuado tratamiento. La gammagrafía 
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SPECT-CT con 111In-pentetreótida puede detectar paragangliomas, principalmente en aque-
llos casos de localización atípica o no sospechada, y puede tener un papel significativo en el 
seguimiento de los pacientes diagnosticados con paraganglioma multifocal y familiar. Caso 
clínico: Se presenta un caso de un paraganglioma mediastínico medio extremadamente raro, 
detectado por gammagrafía y SPECT-CT con 111In-pentetreótida en un paciente diagnosticado 
de historia multifocal y familiar de paraganglioma. La cirugía se realizó mediante esternotomía 
media y circulación extracorpórea. El examen patológico de la muestra quirúrgica mostró un 
tumor paraórtico de bajo grado, positivo para cromogranina y sinaptofisina, citoqueratina AE1-
AE3 negativo y Ki67 menor de 5%, compatible con paraganglioma. Actualmente, el paciente 
está libre de tumores, bajo supervisión clínica. Conclusiones: La exploración con 111In-pente-
treótida demostró ser un método de diagnóstico útil debido a su potencial para explorar todo 
el cuerpo, por lo que permite localizar paragangliomas insospechados y de localización atípica. 
Este hallazgo sugiere que los pacientes diagnosticados con paraganglioma multifocal de ca-
beza y cuello deben someterse a un seguimiento periódico con 111In-pentetreótida para detec-
tar paraganglioma no sospechado. 
 




Paragangliomas are low incidence neuroendo-
crine tumors that express somatostatin recep-
tors, being type 2 the most common of them [1, 
2]. They arise from the neural crest of the au-
tonomic nervous system and are usually be-
nign slow growing lesions, which can produce 
compressive clinic or neurological dysfunction 
due to an involvement of adjacent nerves. Its 
most common location is head and neck, being 
the carotid glomus or carotid chemodectomas 
the most frequent of all its forms [3, 4]. 
Diagnosis is based on structural imaging tests 
such as magnetic resonance imaging (MRI), 
computed tomography (CT) or angiography 
and functional imaging tests, as 111In-Pen-
tetreotide scintigraphy. One of the main diag-
nostic indications of Nuclear Medicine tests is 
the suspicion of paragangliomas in areas of dif-
ficult biopsy access and/or in cases of atypical 
locations, which require differential diagnoses 
with other pathologies [1]. 
Here we report a case of an extremely rare 
middle mediastinal paraganglioma, detected 
by scintigraphy and SPECT-CT with 111In-Pen-
tetreotide in a patient diagnosed of multifocal 




A 54-year-old male was diagnosed in 1997 of 
family and multifocal paraganglioma (bilateral 
carotid and right jugular tympanic paragangli-
oma). He underwent surgery and all paragan-
gliomas were excissed. Afterward, he stayed 
asymptomatic with no evidence of residual dis-
ease or recurrence by structural techniques 
and octreotide and being discharged in 2005. 
In 2013, he returns to our Hospital for a follow-




Figure 1. Aortic paraganglioma. 111In-Pentetreotide planar 
scintigraphy and SPECT-CT images show weak focal up-
take in mediastinum, adjacent to ascendant Aorta. Histo-
logic study was recommended.  
Otoscopy and analytical study showed no ab-
normalities and 111In-Pentetreotide scintigra-
phy was requested to evaluate rest or recur-
rence of paraganglioma. The study showed 
weak uptake in the left jugular region, what led 
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to the suspicion of tumor recurrence, and a re-
view was scheduled within a year. 
New scintigraphic control was performed in 
October 2014, showing the previously de-
scribed weak focal uptake and the appearance 
of a new focus in the anterior mediastinum 
(Figure 1).  
Thoracic SPECT-CT fusion images located the 
mediastinal focus adjacent to aorta and pulmo-
nary trunk (Figure 1). Given this finding, con-
trast enhanced CT scan and an angiography 
were performed. CT scan reported a nodule of 
15 x 18 mm in aortopulmonary window, adja-
cent to the aortic root, in contact with the left 
coronary sinus.  
The angiography showed nodule irrigation by 
septal coronary branch. No MRI was per-
formed because of multiple ferromagnetic 
plates in both lower limbs, due to an accident 
suffered by the patient 20 years ago. 
Given these findings, surgical treatment of the 
mediastinal lesion was planned. Surgery was 
carried out by median sternotomy and extra-
corporeal circulation. The pathological exami-
nation of the surgical specimen showed a para-
aortic low-grade tumor, positive for chro-
mogranin and synaptophysin, cytokeratin AE1-
AE3 negative and Ki67 lower than 5%, compat-
ible with paraganglioma (Figure 2). Currently, 





Mediastinal paragangliomas are extremely 
rare. They are most commonly located in the 
posterior mediastinum, with its origin in 
paraspinal ganglia, while those located in the 
middle mediastinum arise from the para-aortic 
lymph node chains. Its low-frequency forces to 
establish a differential diagnosis with other pa-
thologies such as thymoma, thymic carcinoma, 
metastases or angiosarcoma. However, these 
pathologies do not express somatostatin re-
ceptors, so 111In-Pentetreotide scintigraphy ex-
clude them [5, 6, 7]. 
The first line diagnosis of paraganglioma is the 
study of biochemical parameters and structural 
imaging tests (CT, MRI). Scintigraphy and 
SPECT/CT with 111In-Pentetreotide have good 
levels of sensitivity (93%) and specificity 
(86,5%) for the detection of head and neck 
paragangliomas [3, 7, 8]. FDG PET studies are 
especially useful in cases with negative scintig-
raphy and positive mutation for succinate de-
hydrogenase gene (SDHX) [9]. In this case, the 
patient showed negative biochemical tests and 
SPECT/CT with 111In-Pentetreotide identified 
the para-aortic lesion accurately, allowing its 





Figure 2. Its histology consists of two main celular types: 
epitelial (3A) and peripherical sustentacular cells; Both in-
volved in a highly vascularized stroma. The presence of 
citological atypia and celular pleomorfism (3B) are not a 
sign of agressiveness, as this is determined by the pres-
ence of necrosis, mitosis and capsular invasión. Its 
inmunohistochemical features are: Sinaptophis-
ine/cromogranin positive (major cells) (3C) and s-100 sus-
tentacular cells (3D) with a low (Ki-67) proliferation index. 
Citocheratin (actin and desmin) expression were negative. 




In conclusion, we report the case of a 54 years old 
male with multifocal and family history of paragangli-
oma 17 years ago, who currently presented an ex-
tremely rare asymptomatic middle mediastinal para-
ganglioma, diagnosed by planar and SPECT/CT 
with 111In- Pentetreotide scan.  
 
This procedure proved to be a helpful diagnos-
tic method because of its potential to explore 
full body, so It allows us to locate unsuspected 
and atypical location paragangliomas. This find-
ing suggests that patients diagnosed with multifocal 
head and neck paraganglioma should undergo peri-
odical follow-up with 111In-Pentetreotide scan to de-
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